PMC:6723065 / 7278-8208 JSONTXT

{"project":"2_test","denotations":[{"id":"31434341-1538221-7278229","span":{"begin":232,"end":234},"obj":"1538221"},{"id":"31434341-8629680-7278230","span":{"begin":608,"end":610},"obj":"8629680"},{"id":"31434341-10648440-7278231","span":{"begin":611,"end":613},"obj":"10648440"},{"id":"31434341-10607098-7278232","span":{"begin":926,"end":928},"obj":"10607098"}],"text":"Clonazepam and melatonin are first-line treatments for RBD. Clonazepam is a long-lasting benzodiazepine, which does not suppress motor tone during REM sleep but prevents dream enactment behavior onset, through uncertain mechanisms [25]. The treatment dose is 0.5 to 2.0 mg before bedtime and it is rarely associated with dosage tolerance and side effects (\u003c10% of cases), such as daytime sedation, worsening of obstructive and central sleep apnea, alopecia, depression, memory impairment, and gastroesophageal reflux. Thus, Clonazepam is completely or partially successful in up to 90% of patients with RBD [32,33]. Although it is the most common used drug for RBD, current evidence about its effectiveness have only been based on observational studies (retrospective cohorts and case-series). In addition, clinical studies have been conducted with small cohorts of patients and without using PSG to value treatment response [34]."}